The PI of the trial, with hindsight, is not surpri
Post# of 148190
(Total Views: 746)
Posted On: 09/12/2024 9:00:54 PM
The PI of the trial, with hindsight, is not surprised they missed primary and secondary endpoints.
https://www.healio.com/news/cardiology/202302...rapy-in-hf
I find it fascinating from a layperson's perspective that macrophage state is opposite between MPC and leronlimab therapies yet both seem effective. Mesoblast has a January PDUFA date for pediatric aGvHD.
https://www.healio.com/news/cardiology/202302...rapy-in-hf
I find it fascinating from a layperson's perspective that macrophage state is opposite between MPC and leronlimab therapies yet both seem effective. Mesoblast has a January PDUFA date for pediatric aGvHD.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼